MARC details
| 000 -LEADER |
|---|
| fixed length control field |
13790namaa22004211i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20241219161218.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
241218s2023 |||a|||f m||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
572 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
572 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.08.01.M.Sc.2023.Sa.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Safeya Abdelfattah Abdelrahman, |
| Preparation |
preparation. |
| 245 14 - TITLE STATEMENT |
|---|
| Title |
The Possible Association of Some Long-Non Coding RNAs & ABO Blood Groups with Acute Lymphoblastic Leukaemia in Egyptian Children/ |
| Statement of responsibility, etc. |
Safeya Abdelfattah Abdelrahman ; Supervisors: Dr. Hanan Muhammad Abdelgawa, Dr. Noha Hussein Sayed, Dr. Mahmoud Hammad Mahmoud. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
الإرتباط المحتمل بين بعض أحماض الريبونيوكليك الطويلة الغير مشفرة وفصائل الدم مع سرطان الدم الليمفاوي الحاد في الأطفال المصريين/ |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2023. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
108 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.) -Cairo University, 2023. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 79-108. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Leukemia is the most frequent form of childhood malignancy, accounting for <br/>30% of cases of childhood cancer. Although there are some associations with host <br/>and environmental factors, most pediatric leukemia cases are idiopathic. <br/>In children, the most common type of leukemia is acute lymphoblastic <br/>leukemia (ALL). ALL affects the immature forms of white blood cells, called <br/>lymphoblasts. B-lymphocytes and T-lymphocytes are the two basic types of <br/>lymphocytes, and their immature forms are the source of the two corresponding <br/>subsets of ALL, T-ALL and B- or pre-B ALL.<br/>Long non-coding RNAs (LncRNAs) regulate several biological processes <br/>including differentiation, development and biogenesis. Many human illnesses, <br/>including some cancers, are associated with lncRNA dysregulation.<br/>LncRNA ANRIL, located in the human chromosome 9p21 region, has been <br/>reported to be involved in tumor progression. ANRIL has been found to regulate <br/>gene expression via recruiting polycomb repressor complex (PRC) 1 and 2 or <br/>titrating miRNA; it also participates in signaling pathways. ANRIL was reported to <br/>be overexpressed in many cancer types and is capable of promoting cell <br/>proliferation and cell cycle progression, and inhibiting apoptosis and senescence. <br/>Furthermore, ANRIL has the potential to serve as a biomarker for diagnosis and <br/>prognosis of several cancers.<br/>CDKN2A, located on the same locus as does ANRIL, is frequently <br/>inactivated or deleted in multiple hematological malignancies and this is a frequent <br/>event in childhood B- and T-lineage ALL.<br/>LncRNA LINC-PINT plays a critical role in many diseases, especially <br/>cancer. In most human tumors, LINC-PINT is down-regulated where it serves as a <br/>tumor suppressor.<br/>HMOX1 is a LINC-PINT associated gene. Its activity prevents the oxidative <br/>stress and inflammation of cells. The cytoprotective effects of HMOX1 are exerted <br/>by itself or mediated by its products.<br/>Different studies have reported conflicting results on the differential <br/>distribution of blood groups in acute leukemia patients. <br/>The current study aimed to investigate the possible association between the <br/>two lncRNAs; ANRIL and LINC-PINT and their downstream targets - CDKN2A <br/>and HMOX1, respectively - with ALL in children. The differential distribution of <br/>ABO blood groups among ALL patients was also studied. This work was further <br/>extended to elucidate the possible correlation of ANRIL, LINC-PINT, CDKN2A, <br/>HMOX1 and ABO blood groups with the patients‟ clinicopathological data. The <br/>Summary and Conclusion<br/>76<br/>novelty of this study was investigating the impact of initial treatment till the end of <br/>remission induction phase on the studied parameters. <br/>This case-control study was carried out on 66 Egyptian pediatric patients <br/>newly diagnosed with ALL with range of age 1-17 years. A group of 39 age- and <br/>sex-matched children was recruited as a control group. <br/>Patients were treated at the National Cancer Institute-Cairo University and <br/>Dar El-Salam hospital. Patients who died before end of remission induction, had <br/>relapsing ALL, had other types of leukemia, were under steroid for any other <br/>disease, or those with inadequate samples were excluded. All children were <br/>recruited during the period from December 2020 to March 2022. <br/>Each participant‟s guardian provided written consent at enrollment after <br/>discussing the experimental procedure and the beneficial expectancies. The study <br/>protocol and all procedures performed were approved by the Research Ethics <br/>Committee for experimental and clinical studies at the Faculty of Pharmacy, Cairo <br/>University, Cairo, Egypt (approval number: BC 2458) and conformed to the 1975 <br/>Helsinki declaration, revised in 2008. <br/>Peripheral blood samples were collected from all patients at their routine time <br/>of sampling at the initial investigation, another sample was collected at the end of <br/>remission induction phase (43-46 days from diagnosis). Similarly, blood samples <br/>were taken from controls. Each blood sample was divided into 3 aliquots. One <br/>aliquot was used for blood group typing, the second one was used for total RNA <br/>extraction for measuring of ANRIL, CDKN2A and LINC-PINT expression levels <br/>using quantitative real time PCR (RT-qPCR), and a third aliquot was used for <br/>serum separation to measure protein level of HMOX1 by Human HMOX1 ELISA <br/>Kit.<br/>Results of the current study showed a significant upregulation of lncRNA <br/>ANRIL and CDKN2A plasma expression levels in the newly diagnosed patients <br/>compared to controls. However, both demonstrated a downturn at the end of <br/>remission induction that did not reach significant levels as compared to their levels <br/>at diagnosis.<br/>Moreover, newly diagnosed ALL patients showed a dramatic downregulation <br/>of LINC-PINT expression and HMOX1 protein level compared to control levels. In <br/>addition, both showed significant increase at the end of remission induction as <br/>compared to admission levels.<br/>Furthermore, significant positive correlations were found between ANRIL <br/>and CDKN2A and between LINC-PINT and HMOX1.<br/>Summary and Conclusion<br/>77<br/>There was a significant positive association between ANRIL with both risk <br/>stratification and MRD at the end of remission induction phase. Surprisingly, <br/>LINC-PINT showed a positive significant association with CNS status as well as <br/>MRD at the end of remission induction, while HMOX1 was positively associated <br/>with risk stratification and IPT. Of note, no significant association was found <br/>between ANRIL, LINC-PINT or HMOX1 with other data including age, sex or <br/>TLC. Regarding CDKN2A, no significant association was observed with any of the <br/>ALL clinicopathological features. It was only associated with sex, showing higher <br/>expression levels among boys.<br/>ROC curve analysis showed good diagnostic performance for LINC-PINT <br/>followed by CDKN2A then ANRIL, while an excellent diagnostic performance <br/>was observed for HMOX1.<br/>Logistic regression analysis indicated that LINC-PINT and HMOX1 were <br/>significant predictors in the univariate analysis. In a stepwise forward multivariate <br/>analysis, HMOX1 turned out to be significant independent variable<br/>Concerning blood group distribution in ALL patients, notably, blood group A <br/>was the most observed blood group (36.36%). However, no significant difference <br/>was found between controls and ALL patients regarding the distribution of any of <br/>the ABO blood groups. Similarly, there was no significant association between <br/>ABO blood groups and the patients‟ clinicopathological data.<br/>Finally, we can conclude that:<br/>1. ANRIL, CDKN2A, LINC-PINT and HMOX1 might be associated with the <br/>susceptibility of ALL in pediatric patients. <br/>2. ANRIL and LINC-PINT were associated with poor response of patients to <br/>treatment.<br/>3. There was a significant positive association between ANRIL and HMOX1 <br/>with risk stratification. The later was also linked to IPT, while LINC-PINT <br/>showed a positive significant association with CNS status.<br/>4. The initial treatment brought ANRIL to a level approaching control‟s level <br/>and moderated the levels of both LINC-PINT and HMOX1.<br/>5. The study parameters had remarkable diagnostic potential in discriminating <br/>ALL patients, where HMOX1 had superior diagnostic power and it was the <br/>only one demonstrating as significant independent predictor of ALL.<br/>Summary and Conclusion<br/>78<br/>6. There was no considerable difference in ABO blood group distribution <br/>between patients and controls, nor were there any associations between <br/>blood groups and patients‟ clinicopathological data. <br/>Lastly, this study has some limitations. To begin with, patients in the current <br/>study were only recruited from National Cancer Institute-Cairo University and Dar <br/>El-Salam hospital, which necessitates comparable multi-centered studies to obtain <br/>more data and compare outcomes. Furthermore, the impact of COVID-19 <br/>pandemic affected our ability to collect more samples as it was the timeframe of the <br/>study. Future studies with larger sample size need to be conducted to replicate the <br/>current results.<br/> |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
يعد سرطان الدم الشكل الأكثر شيوعًا للأورام الخبيثة في مرحلة الطفولة، حيث يمثل۳۰ ٪ من حالات سرطان الأطفال. على الرغم من وجود بعض الارتباط بين العوامل الذاتية والبيئية مع المرض، إلا أن معظم حالات سرطان الدم لدى الأطفال مجهولة السبب.<br/>يعتبر سرطان الدم الليمفاوي الحاد هو النوع الأكثر انتشارًا لسرطان الدم في الأطفال. يؤثر سرطان الدم الليمفاوي الحاد على التكوينات غير الناضجة لخلايا الدم البيضاء التي تسمى الخلايا الليمفاوية. وثمة نوعان من الخلايا الليمفاوية: الخلايا الليمفاوية البائية والخلايا الليمفاوية التائية.وقد ينشأ سرطان الدم الليمفاوي الحاد من أي من نوعي الخلايا الليمفاوية، ولذلك فإن حالات سرطان الدم الليمفاوي الحاد تعرف بأنها سرطان الدم الليمفاوي الحاد للخلية باء (B-ALL) أو الخلية تاء(T-ALL) .<br/>تنظم الأحماض النووية الريبوزية الطويلة الغير مشفرة العديد من العمليات البيولوجية بما في ذلك تميز وانقسام الخلايا والتكوين البيولوجي لها. ترتبط العديد من الأمراض البشرية، بما في ذلك بعض أنواع السرطان، بخلل في مستويات الأحماض النووية الريبوزية الطويلة الغير مشفرة.<br/>ومن الأحماض التي تم دراسة دورها في هذا البحثANRIL والموجود في منطقة الكروموسوم البشري 9p21، وقد تم اثبات صلته بتطور الأورام حيث يستطيع ANRILتنظيم التعبير الجيني عن طريق ارتباطه بوحدتي بروتين الـpolycomb أو عن طريق التأثير على الأحماض النووية الريبوزية متناهية الصغر(miRNA) كما يشارك في مسارات الاشارات. وقد وجد أن مستوى ANRILيزيد في العديد من أنواع السرطان، وانه قادر على تعزيز تكاثر وتطور دورة الخلايا، وتثبيط موت الخلايا المبرمج والشيخوخة. علاوة على ذلك، فإن ANRIL لديه القدرة على العمل كمؤشر حيوي لتشخيص العديد من أنواع السرطان.<br/>يقع CDKN2A في نفس الموقع الجيني للـANRIL و غالبا ما يتم تثبيطه أو حذفه في العديد من أورام الدم الخبيثة، كما يشيع ذلك في سرطان الدم الليمفاوي الحاد بنوعيه لدى الاطفال.<br/>يلعب الحمض الريبوزي النووي الطويل الغير مشفرLINC-PINT دورًا حاسمًا في العديد من الأمراض، وخاصة السرطان. إذ يقل مستوى LINC-PINT في معظم الأورام حيث يعمل كمثبط للورم.<br/>يرتبط جين HMOX1 بـ LINC-PINT، و يمنع الاجهاد التأكسدي والتهاب الخلايا عندما يكون نشطًا. يرجع تأثير HMOX1 في حمايته للخلايا إلى تأثيره المباشر أو بواسطة منتجاته.<br/>أثبتت الدراسات المختلفة نتائج متضاربة حول التباين في توزيع فصائل الدم لدى مرضى سرطان الدم الحاد. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Biochemistry |
| Source of heading or term |
qrmak |
| 653 #0 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Childhood ALL |
| -- |
ANRIL |
| -- |
CDKN2A |
| -- |
LINC-PINT |
| -- |
HMOX1 |
| -- |
ABO blood groups |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hanan Muhammad Abdelgawa |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Noha Hussein Sayed |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mahmoud Hammad Mahmoud |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2023 |
| Supervisory body |
Hanan Muhammad Abdelgawa |
| -- |
Noha Hussein Sayed |
| -- |
Mahmoud Hammad Mahmoud |
| Universities |
Cairo University |
| Faculties |
Faculty of Pharmacy |
| Department |
Department of Biochemistry |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Aya Mohamed |
| Reviser Names |
Huda |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |
